Duane Roth Endowed Award Lecture

2020 Symposium

2019 Symposium

2019 Symposium Photo Gallery

2018 Symposium

2017 Symposium

2017 Symposium Photos

2016 Symposium

2015 Symposium

2015 Agenda and Bios

2015 Symposium Photos

2014 Symposium

2014 Agenda and Bios

2013 Featured Talks

2013 Symposium Photos

Previous Symposia

2020 Symposium


The 16th Industry/Academia "Next Generation Precision Oncology" Symposium will be held on Thursday, February 20, 2020.

Keep checking this page for updates.



Program Agenda



8:00AM

Registration and Continental Breakfast
8:30AM

Organizer Welcome
  • Ida Deichaite, PhD, Organizer, UC San Diego Moores Cancer Center
8:35AM

Director’s Welcome: Precancer 2020
  • Scott Lippman, MD, Director, UC San Diego Moores Cancer Center
8:45AM

  • The Emergence of a Pre-Cancer Genomics Atlas
    Ludmil Alexandrov, PhD, UC San Diego Moores Cancer Center
9:00AM

Session: Solid Tumors
  • Chair: J. Silvio Gutkind, PhD, UC San Diego Moores Cancer Center
9:05AM

  • Targeting extrachromosomal DNA (ecDNA), a new approach to treating cancers with high copy number gene amplification
    Zachary Hornby, Boundless Bio
9:20AM

  • Platform Approach to Pancreatic Cancer Therapy
    Gregory Botta, MD, PhD, UC San Diego Moores Cancer Center
9:35AM

  • Pancreatic Cancer Organoids Enable Precision Medicine
    Herve Tiriac, PhD, UC San Diego Moores Cancer Center
9:50AM

  • The Pathology of RET-altered Lung and Thyroid Cancers
    Anthony Sireci, MD, & Cynthia Rubenstein, PhD, Loxo Oncology at Lilly
10:05AM

  • KRAS G12C Inhibition: Opportunities for intersection of targeted therapy and immune checkpoint modifiers
    James Christensen, PhD, Mirati Therapeutics
10:20AM

Session Q&A and Discussion
10:35AM

Break
10:45AM

Duane Roth Achievement Award Presentation
  • Recipient Scott Gottlieb, MD,
    23rd Commissioner of the FDA, AEI Resident Fellow, NEA Partner
10:55AM

Keynote Presentation:
Duane Roth Award Lecture
  • Opportunities through public to advance the care of cancer patients
    Scott Gottlieb, MD, 23rd Commissioner of the FDA, AEI Resident Fellow, NEA Partner
12:00PM

Lunch & Poster Session
1:30PM

Session: Immuno-Oncology
  • Chair: Ezra Cohen, MD, UC San Diego Moores Cancer Center
1:35PM

  • Enabling adoptive cellular therapy against natural ligands
    Stephen Schoenberger, PhD, La Jolla Institute for Immunology, SDCPI, UCSD
1:50PM

  • Patient Experience
    Tamara Strauss, Patient Advocate
2:00PM

  • Personalized NeoAg vaccines
    Aaron Miller, MD, PhD, UC San Diego Moores Cancer Center
2:15PM

  • Development of genetically engineered T cell products for cancer therapy
    Adrian Bot, MD, PhD, Kite, a Gilead Company
2:30PM

  • The Yin and Yang of CAR T: Reaching the Full Potential of Cell Therapy
    William Go, MD, PhD, A2 Biotherapeutics
2:45PM

  • Pluripotent Cell-Derived Engineered T and NK Cells as a Cornerstone Approach for Off-the-Shelf Cancer Immunotherapy
    Bob Valamehr, PhD, Fate Therapeutics
3:00PM

Session Q&A and Discussion
3:15PM

Break
3:25PM

Session: Hematology/Oncology
  • Chair: Catriona Jamieson, MD, PhD, UC San Diego Moores Cancer Center
3:30PM

  • State of the Art Experimental Models for Aggressive Multiple Myeloma
    Fotios Asimakopoulos, MD, PhD, UC San Diego Moores Cancer Center
3:45PM

  • Protein Neddylation: A New Target for Therapeutics in Acute Myeloid Leukemia
    Ronan Swords, MD, PhD, AbbVie
4:00PM

  • Precision Therapy of Relapsed/Refractory EBV+ Lymphomas Utilizing an Oral Inducer of Viral Kinases to Activate an Anti-tumor Prodrug
    Ivor Royston, MD, Viracta Therapeutics
4:15PM

Session Q&A and Discussion
4:35PM

  • Fireside Chat: Are we about to see the full value of diagnostics realized across drug development and patient care?
    Mike Pellini, MD, Section 32
    Moderated by Ian Stone, Canale Communications
5:05PM

Closing Remarks
  • Catriona Jamieson, MD, PhD, UC San Diego Moores Cancer Center
5:10PM

Symposium Reception at Goldberg Auditorium Foyer



Speaker biographies are available here.



COI Policy: Disclosure of Relationships with Companies


The Symposium strives for independence, objectivity, transparency, and scientific rigor in all its activities through appropriate disclosure and management of financial relationships, among other things. The Symposium Policy for Relationships with Companies (COI Policy), in compliance with UC San Diego and University of California Office of the President (UCOP) COI policies (available at this link), was developed to help guide the management of potential conflicts, primarily through disclosure of all financial relationships that might result in actual, potential, or perceived conflicts of interest.

The Symposium requires participants in its activities—and all faculty and committee members— to disclose all of their financial relationships with for-profit health care companies. The Symposium’s Policy is not intended to create a presumption of impropriety based on the existence of financial relationships with companies, rather the goal is to achieve full transparency through the disclosure of those relationships. Although the Symposium Policy relies primarily on disclosure of financial relationships, it also recognizes that some relationships cannot be managed with disclosure alone and identifies additional management steps in this case.

The Symposium wants to help participants in its activities to successfully report their disclosures. To that end, the Symposium uses a general disclosure model, requiring disclosure of all relationships.

We Thank Our Supporters for the 2020 Symposium:










Supported by an Educational Grant from Celgene